Miriam Nickel

Miriam Nickel

Auto-generated profile, based on publicly available information

Miriam Nickel

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
MNMiriam Nickel
Miriam Nickel
ASAlessandro Simonati
Alessandro Simonati
DJDavid Jacoby
David Jacoby
SLSusanne Lezius
Susanne Lezius
DKDirk Kilian
Dirk Kilian
ASAngela Schulz
Angela Schulz

1 April 2017 in Pediatric Neurology
Verified
Journal Article
Open access
RWRuth Williams
Ruth Williams
HAHeather R. Adams
Heather R. Adams
MBMartin Blohm
Martin Blohm
JCJessica L. Cohen-Pfeffer
Jessica L. Cohen-Pfeffer
EREmily de Los Reyes
Emily de Los Reyes
ASAngela Schulz
Angela Schulz
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.

1 October 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
FPFélixe Pelletier
Félixe Pelletier
SPStefanie Perrier
Stefanie Perrier
FCFerdy K Cayami
Ferdy K Cayami
AMAmytice Mirchi
Amytice Mirchi
SSStephan Saikali
Stephan Saikali
GBGeneviève Bernard
Geneviève Bernard
Context 4H or POLR3-related leukodystrophy is an autosomal recessive disorder typically characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism, caused by biallelic pathogenic variants in POLR3A, POLR3B, POLR1C, and POLR3K. The endocrine and growth abnormalities associated with this disorder have not been thoroughly investigated to date. Objective To systematically characterize endocrine abnormalities of patients with 4H leukodystrophy. Design An international cross-sectional study was performed on 150 patients with genetically confirmed 4H leukodystrophy between 2015 and 2016. Endocrine and growth abnormalities were evaluated, and neurological and other non-neurological features were reviewed. Potential genotype/phenotype associations were also investigated. Setting This was a multicenter retrospective study using information collected from 3 predominant centers. Patients A total of 150 patients with 4H leukodystrophy and pathogenic variants in POLR3A, POLR3B, or POLR1C were included. Main Outcome Measures Variables used to evaluate endocrine and growth abnormalities included pubertal history, hormone levels (estradiol, testosterone, stimulated LH and FSH, stimulated GH, IGF-I, prolactin, ACTH, cortisol, TSH, and T4), and height and head circumference charts. Results The most common endocrine abnormalities were delayed puberty (57/74; 77% overall, 64% in males, 89% in females) and short stature (57/93; 61%), when evaluated according to physician assessment. Abnormal thyroid function was reported in 22% (13/59) of patients. Conclusions Our results confirm pubertal abnormalities and short stature are the most common endocrine features seen in 4H leukodystrophy. However, we noted that endocrine abnormalities are typically underinvestigated in this patient population. A prospective study is required to formulate evidence-based recommendations for management of the endocrine manifestations of this disorder.

1 January 2018 in Journal of Inborn Errors of Metabolism and Screening
Verified
Journal Article
Open access
PDF file
KWKathleen W. Wyrwich
Kathleen W. Wyrwich
ASAngela Schulz
Angela Schulz
MNMiriam Nickel
Miriam Nickel
PSPeter Slasor
Peter Slasor
TATemitayo Ajayi
Temitayo Ajayi
AKAlfried Kohlschütter
Alfried Kohlschütter
Neuronal ceroid lipofuscinosis type-2 (CLN2) disease is a rare, autosomal recessive, pediatric-onset, neurodegenerative lysosomal storage disease caused by mutations in the TPP1 gene. Cerliponase alfa (Brineura®), a recombinant form of human tripeptidyl peptidase-1, was recently developed as a treatment for CLN2 disease. In clinical trials, the primary end point to evaluate treatment effect was the aggregate score for the motor and language (ML) domains of the CLN2 Clinical Rating Scale, an adaptation of the Hamburg scale’s component items that include anchor point definitions to allow consistent ratings in multinational, multisite, clinical efficacy studies. Psychometric analyses demonstrated that the ML score of the CLN2 Clinical Rating Scale and individual item scores are well defined and possess adequate measurement properties (reliability, validity, and responsiveness) to demonstrate a clinical benefit over time. Additionally, analyses comparing the CLN2 Clinical Rating Scale ML ratings to the Hamburg scale’s ML ratings demonstrated adequate similarity.

2 December 2014 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
ULUlrike Löbel
Ulrike Löbel
FSFerdinand Schweser
Ferdinand Schweser
MNMiriam Nickel
Miriam Nickel
ADAndreas Deistung
Andreas Deistung
RGRegine Grosse
Regine Grosse
JSJan Sedlacik
Jan Sedlacik
Therapeutic trials for Neurodegeneration with Brain Iron Accumulation have aimed at a reduction of cerebral iron content. A 13‐year‐old girl with mitochondrial membrane protein‐associated neurodegeneration treated with an iron‐chelating agent was monitored by R2 relaxometry, R2* relaxometry, and quantitative susceptibility mapping to estimate the brain iron content. The highly increased brain iron content slowly decreased in the substantia nigra but remained stable for globus pallidus. The estimated iron content was higher by R2* compared to R2 and quantitative susceptibility mapping, a finding not previously observed in the brain of healthy volunteers. A hypothesis explaining this discrepancy is offered.

26 May 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ULU. Löbel
U. Löbel
JSJ. Sedlacik
J. Sedlacik
MNM. Nickel
M. Nickel
SLS. Lezius
S. Lezius
JFJ. Fiehler
J. Fiehler
ASAngela Schulz
Angela Schulz
BACKGROUND AND PURPOSE: Experimental therapies for ceroid lipofuscinosis, neuronal, 2 (CLN2), a genetic disorder of childhood associated with progressive brain atrophy, are currently being developed. Because quantitative descriptions of the natural course of brain volume loss are needed to evaluate novel therapies, we performed MR imaging volumetry of patients with CLN2 to identify a suitable MR imaging marker of disease progression. MATERIALS AND METHODS: Thirteen patients (8 females, 5 males) were recruited from a prospective natural disease cohort of patients with neuronal ceroid lipofuscinosis. Repeated MR imaging volumetric analysis (29 datasets) was performed by using the FreeSurfer Software Suite. Follow-up time ranged from 8 months to 5.3 years. MR imaging–segmented brain volumes were correlated to patient age and clinical scores. RESULTS: Segmented brain volumes correlated significantly with patient age (lateral ventricles, r = 0.606, P = .001; supratentorial cortical GM, r = −0.913, P < .001; supratentorial WM, r = −0.865, P < .001; basal ganglia/thalamus, r = −0.832, P < .001; cerebellar GM, r = −0.659, P < .001; cerebellar WM, r = −0.830, P < .001) and clinical scores (lateral ventricles, r = −0.692, P < .001; supratentorial cortical GM, r = 0.862, P < .001; supratentorial WM, r = 0.735, P < .001; basal ganglia/thalamus, r = 0.758, P < .001; cerebellar GM, r = 0.609, P = .001; cerebellar WM, r = 0.638, P < .001). Notably, supratentorial cortical GM showed a uniform decline across the patient cohort. During late stages of the disease when the clinical score was zero, segmented brain volumes still correlated with patient age; this finding suggests that MR imaging volumetry allows quantitative assessment of disease progression at stages when it cannot be detected by clinical assessment alone. CONCLUSIONS: Automated MR imaging volumetry, as a nonsubjective and highly sensitive tool, is feasible in CLN2 disease and provides a quantitative basis to evaluate novel experimental therapies.